CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Cell cycle analysis of CML CD34+ cells, revealed they were more sensitive to all treatment arms than normal CD34+, with a significant increase in cells in sub-G0 following dual treatment with LDN + IM, DOR alone and DOR + IM (Fig. 3e–ii).